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Abstract
Introduction: The study aimed to compare the effect of obesity with and without metabolic syndrome  on asthma severity, quality 
of life, sleep quality, sleep disordered breathing and inflammatory markers as compared to non-obese asthma patients. 
Material and methods: 60 asthma patients recruited for the study were divided equally into non-obese (NOA), obese without 
metabolic syndrome (OANMS) and obese with metabolic syndrome (OAMS) groups. Study cohorts were assessed for severity 
of asthma, quality of life and quality of sleep using questionnaires and inflammatory markers (FENO, hs-CRP, IL-5, IL-6 and leptin).
Institutional ethical committee approved the study.
Results: The results suggests OAMS patients may be a subtype of asthmatics having significantly severe asthma (p < 0.05), poor 
quality of life (p < 0.05), high risk of OSA (p < 0.05), decreased lung volumes (FRC) (p < 0.05), higher levels of inflammatory markers 
(leptin and IL-6) (p < 0.05), and high incidence of sleep disordered breathing (p < 0.05) in comparison to NOA and OANMS patients. 
Conclusions: The present study has shown that obese asthmatics especially with metabolic syndrome represent a subtype of 
asthmatic population. Hence, the treatment of metabolic syndrome may be necessary in addition to asthma to achieve optimal 
control. 
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Introduction
Asthma and obesity represent growing epide-
mics both in the developing and in the developed 
world [1]. The parallel rise in the prevalence of 
asthma and obesity suggests that these disorders 
maybe linked. There is an increased prevalence 
of asthma in the obese and/or overweight subject; 
also obesity may be more prevalent in asthmatics 
than in non-asthmatics [2].
The obese-asthma phenotype is represented 
by a  scarcity of airway inflammation. Obesity 
may predispose to increased Th2 inflammation 
or tendency to atopy, however other mechanisms 
independent of inflammatory infiltrates need to be 
studied, such as hyperglycemia, hyperinsuline-
mia and dyslipidemia in the context of metabolic 
syndrome. The metabolic syndrome is a cluster of 
risk factors that include hypertension, impaired 
glucose tolerance or diabetes mellitus, central 
obesity and dyslipidemia [3]. According to the 
HUNT study, metabolic syndrome is a risk factor 
for asthma [4].
Sleep disordered breathing (SDB), a  con-
dition frequent in obese individuals, may exacer-
bate asthma leading to its increased severity [5]. 
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Recently, changes in the expression of pro-in-
flammatory mediators such as leptin, IL-6, TNF-a, 
C-reactive protein and adiponectin have been 
demonstrated in obese asthmatics, implying their 
potential role in the pathogenesis of obesity- 
-associated asthma [6]. Exhaled breath nitric oxi-
de (FENO) levels are strongly and independently 
associated with respiratory impairment as well as 
bronchial hyper responsiveness [7].
The present study was consequently planned 
to compare the effect of obesity with and without 
metabolic syndrome on asthma severity, quality of 
life, sleep quality, SDB and inflammatory markers 
in comparison to non-obese asthma patients. 
Material and methods
Patients diagnosed with asthma in line with 
the Global Initiative for Asthma (GINA) guide-
lines were enrolled for the study from the out-
patient clinics [8]. A total of 60 asthma patients 
(32 females and 28 males) aged between 15 and 
60 years were evaluated and were divided into 
3 equal groups consisting of 20 patients each. The 
patients with BMI < 25 kg/m2, were defined as 
non-obese and BMI ≥ 25 kg/m2 were defined as 
overweight/obese [9]. The presence of metabolic 
syndrome was detected in line with the NCEP ATP 
III definition [10], if any 3 or more of the following 
were present 1) elevated waist circumference: 
men ≥ 90 cm, women ≥ 80 cm, 2) raised triglyce-
ride (TG) > 150 mg/dL or on specific treatment for 
this lipid abnormality, 3) reduced HDL cholesterol 
< 40 mg/dL in males, < 50 mg/dL in females or 
on specific treatment for this lipid abnormality, 
4) raised blood pressure: systolic > 130 mm Hg or 
diastolic > 85 mm Hg, or treatment of previously 
diagnosed hypertension, 5) raised fasting plasma 
glucose > 100 mg/dL or diagnosed type 2 diabetes. 
On evaluation of the above mentioned factors 
the patients were divided into 3 equal groups 
consisting of 20 patients each into: Group 1 — 
Non-obese asthmatics (NOA), Group 2 — Obese 
asthma without metabolic syndrome (OANMS) 
and Group 3 — Obese asthma with metabolic 
syndrome (OAMS). The exclusion criteria were 
1) smoker (former and current smoker), 2) oral 
corticosteroid intake in the preceding month, 3) 
pregnant and lactating females, 4) patients with 
hepatic / neurologic disorder. 
The severity of asthma was classified accor-
ding to the criteria of the 2008 GINA classifica-
tion as intermittent, mild persistent, moderate 
persistent and severe persistent [11]. SDB was 
defined as habitual loud snoring (partner/parent 
report of snoring “louder than talking” 3−4 times 
per week or more on a written questionnaire), and 
oxygen desaturation index (ODI) of 5 or more per 
hour during overnight oximetry monitoring [7]. 
Spirometry was performed on a dry, rolling-
seal spirometer of the benchmark model lung 
function machine (P.K. Morgan, Kent, UK). Maxi-
mal expiratory flow volume curves were obtained 
as per ATS/ERS recommendations 2005 [12]. 
Three acceptable and at least 2 reproducible cu-
rves were obtained in each patient. The highest 
values of FVC and FEV1 were selected. Spirometry 
was repeated 20 mins after inhalation of 200 μgm 
of salbutamol. Static lung volume like residual 
volume (RV) and total lung capacity (TLC) were 
measured. Helium was used to measure TLC [12].
St. George’s  Respiratory Questionnaire 
(SQRQ) measures health impairment in patients 
with asthma and COPD [13]. The questionnaire 
consist of 50 items that survey patient’s  recol-
lection of their symptoms (symptom score), the 
disturbance to patient’s daily physical activity 
(activity scores) and psychosocial dysfunction 
(impact scores).
Asthma Quality of Life Questionnaire (Ju-
nipers Asthma Questionnaire) is a 32-item qu-
estionnaire that measures the functional problems 
that are most troublesome to adults with asthma 
[14]. The items are in four domains (symptoms, 
activity limitations, environmental stimuli and 
emotional function).
Epworth Sleepiness Scale (ESS) evaluates 
general level of sleepiness. The patients were 
rated on 8 situations with a  score of 0 to 30 
(3 being the highest chance of dozing off) [15]. 
The maximum score is 24, and a score greater than 
10 suggests the presence of excessive sleepiness.
Berlin questionnaire is a 10-item questionna-
ire that stratifies patients into a high or low risk 
category for sleep evaluation [16]. The Berlin qu-
estionnaire specifically evaluates snoring history 
and witnessed episodes of apnea (category 1; 5 
questions), tiredness and sleepiness (category 2; 
4 questions), and a history of high blood pressure 
and/or body mass index (BMI) > 30 kg/m2 (cate-
gory 3). Patients who scored positive in 2 of the 
3 domains were considered high risk for OSA.
Pittsburgh Sleep Quality Index (PSQI) is 
a self-rated questionnaire, which assesses sleep 
quality and disturbances over a 1-month time in-
terval. Nineteen individual items generate seven 
“component” scores subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medication, 
and daytime dysfunction [17].
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The patients were kept overnight in the hospi-
tal for overnight pulse oximetry. Overnight pulse 
oximetry was performed with portable Smart link 
Oximeter that gives reading every 4-second. Pa-
tient’s finger was placed inside the sensor for the 
entire sleep duration (minimal of 3 hours sleep). 
Recordings of SpO2 were analyzed. Desaturation 
was considered if there is at least 4% fall in satu-
ration from baseline. ODI was calculated as the 
total number of desaturations divided by the hours 
in bed (at least 3 hours of satisfactory reading) [7]. 
Serum TG level was estimated on fasting blood 
sample using standardized Beckman Coulter diagno-
stic kits on Beckman Coulter Synchron CX5 proc-
linical system. Serum HDL level was estimated on 
Trivitron Healthcare Nanolab — 240 clinical system.
High sensitivity C-reactive protein (hs-CRP), 
Il-5, Il-6, TNFa, values were measured with ELISA 
kits based on quantitative sandwich immunoassay 
as per manufacturer’s  instructions. Serum total 
IgE levels were estimated in all subjects by using 
MINILYSER-TECAN, Austria using Calbiotech kit 
using sandwich enzyme immunoassay technique. 
All subjects, regardless of their atopic status, unde-
rwent measurements of exhales nitric oxide using 
NIOX chemiluminescence analyzer (Aerocrine AB, 
Solna, Sweden) in accordance with the 2005 ATS/
ERS recommendations [18]. 
All patients gave written informed consent to 
participate in the study. The institutional ethical 
committee approved the study protocol.
Statistical analysis
Using SPSS version 15.0 (SPSS, Chicago, IL, 
USA) software the data analysis was performed. 
The data was examined for distribution and 
homogeneity of variances was checked before 
applying parametric tests. The comparison of 
quantitative variables between three groups was 
done using ANOVA/Kruskal-Wallis test. The 
comparison of quantitative variables between 
two groups was done using unpaired t-test/Mann- 
-Whitney test. The comparison of qualitative 
variables between two groups was done using Chi
-square/Fisher’s exact test. Statistical significance 
was used at the conventional 5% level (p < 0.05).
Results
60 patients with asthma, 28 males and 32 
females, who were evaluated, ranged in age from 
17 to 59 years, with duration of symptoms varying 
from 11 months to 31 years. The details of these 
patients are summarized in Table 1. The number 
of patients diagnosed with hypertension and/or 
are on anti-hypertensive drugs were maximum 
in the OAMS group (n = 10; 50%). Similarly, 
patients diagnosed to be diabetic and/or are on 
anti-diabetic drug were maximum in the OAMS 
group (n = 11; 55%). The family history of asthma 
was highest (70%) in the OANMS group. 
The PFT parameters of the 3 groups have 
been described in Table 2. The significant 
pre-bronchodilator obstruction as denoted by 
pre-bronchodilator FEV1/FVC < 70% and signi-
ficant bronchodilator reversibility as denoted by 
change in FEV1 or FVC 200 ml and > 12% change 
from baseline did not show any statistical diffe-
rence between the three groups. 
The questionnaires based assessment of the 
three groups has been described in Table 3. On 
evaluation of has the related quality of life in 
asthma, the SGRQ scores were worst in the OAMS 
Table 1. General characteristics of study population (n = 60), by groupa
Characteristic NOA
(n = 20)
OANMS
(n = 20)
OAMS
(n = 20)
p
Gender*
Male 15 (75) 8 (40) 5 (75) < 0.005
Female 5 (25) 12 (60) 15 (25) < 0.005
Age, years** 30.10 ± 10.41 37.05 ± 11.23 40.90 ± 9.94 < 0.005
BMI, Kg/m2** 22.08 ± 2.11 28.24 ± 2.22 30.42 ± 3.19 < 0.001
Duration of illness, years** 9.80 ± 8.98 13.15 ± 10.63 17.35 ± 13.63 0.106
Dyspnea, years ** 9.80 ± 8.98 13.15 ± 10.63 17.35 ± 13.63 0.106
Cough, years ** 9.80 ± 7.94 13.10 ± 11.15 15.90 ± 13.33 0.084
NOA — non-obese asthmatics; OANMS — obese asthmatics without metabolic syndrome; OAMS — obese asthmatics with metabolic syndrome, and BMI — body 
mass index. NOA group — BMI < 25 kg/m2; OANMS group — BMI ≥ 25 kg/m2 without metabolic syndrome;  OAMS — BMI ≥ 25 kg/m2 with metabolic syndrome; 
avalues expressed as n (%) or mean ± SD; *Chi-square test; **One-way ANOVA and Tukey’s post hoc test
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group, followed by the OANMS and the NOA gro-
up, statistical significance of p < 0.003. However, 
the other Juniper questionnaire did not show 
any statistical difference between the groups. On 
assessment for risk of OSA, maximum number 
of patients with high-risk ESS score (ESS > 10) 
belongs to the OAMS group (p < 0.05). Similar-
ly for Berlin questionnaire, the highest number 
was observed for the OAMS group, followed by 
the OANMS and the NOA groups, though the 
difference did not reach statistical significance. 
In PSQI questionnaire, the quality of sleep was 
the worst in the OAMS group, however, the result 
failed to reach statistical significance. Similarly, 
patients with sleep-disordered breathing were 
highest in the OAMS group, followed by the 
OANMS. None of patient in the NOA group had 
SDB. On assessment of severity of asthma at pre-
sentation, the NOA group had the highest (50%) of 
intermittent asthma, the OANMS had maximum 
. 
Table 3. Variables studying health related quality of life, risk of OSA, quality of sleep, severity of asthma, and SDB in the 
study population (n = 60)a
Variable NOA (n = 20) OANMS (n = 20) OAMS (n = 20)
Health related quality of life in asthma
a) SGRQ- Total score
b) Juniper Questionnaire
27.18 ± 16.70
4.55 ± 0.68
39.99 ± 12.12*
4.27 ± 0.51
42.23 ± 4.35**
4.21 ± 0.59
Risk of OSA
a) Epworth Sleepiness Score (ESS > 10)
b) Berlin questionnaire
4 (20)
3 (15)
10 (50)^
7 (35)
11(55)^^
10 (50)
Quality of sleep
a) Pittsburg Sleep Quality Index (PSQI) 9 (45) 9 (45) 11 (55)
Severity of asthma
a) intermittent
b) mild Persistent
c) moderate Persistent
d) severe Persistent
10 (50)
8 (40)
2 (10)
0
2 (10)
10 (50)
8 (40)#
0
1 (5)
9 (45)
10 (50)##
0
SDB 0 2 (10) 3 (15)%
NOA — non-obese asthmatics; OANMS — obese asthmatics without metabolic syndrome; OAMS — obese asthmatics with metabolic syndrome, and BMI — body 
mass index; OSA — obstructive sleep apnea; SDB — sleep disordered breathing; SGRQ — St. George respiratory questionnaire; NOA group — BMI < 25 kg/m2; 
OANMS group — BMI ≥ 25 kg/m2 without metabolic syndrome; OAMS — BMI ≥ 25 kg/m2 with metabolic syndrome; avalues expressed as n (%) or mean ± SD; 
*p < 0.01 vs. NOA group; **p < 0.01 vs. NOA group; ^p < 0.05 vs. NOA group; ^^p < 0.05 vs. NOA group; #p < 0.005 vs. NOA group; ##p < 0.005 vs. NOA group; 
% p < 0.05 vs. NOA group; One-way ANOVA and Tukey’s post hoc test 
Table 2. Pulmonary function test variables in (% of predicted) in the study population (n = 60)a
Variable NOA
(n = 20)
OANMS
(n = 20)
OAMS
(n = 20)
FVC 96.10 ± 10.80 91.85 ± 12.32 91.60 ± 7.65
FEV1 86.85 ± 13.41 85.25 ± 14.64 84.00 ± 12.8
PEFR 56.75 ± 27.95 54.30 ± 25.61 65.95 ± 43.06
FEF25−75 87.35 ± 24.20 81.45 ± 28.18 94.25 ± 25.48
RV 107.60 ± 55.07 88.70 ± 18.81 98.61 ± 18.52
FRC 109.15 ± 28.21 93.80 ± 21.70* 85.44 ± 16.50**
RV/TLC 111.80 ± 39.56 107.50 ± 28.40 111.56 ± 16.52
TLC 97.30 ± 16.48 90.90 ± 12.26 91.89 ± 7.90
%DLCO 109.21 ± 19.96 101.95 ± 23.01 103.00 ± 23.89
DLCO/VA 124.68 ± 21.83 128.75 ± 26.49 132.94 ± 28.80
NOA — non-obese asthmatics; OANMS — obese asthmatics without metabolic syndrome; OAMS — obese asthmatics with metabolic syndrome, and BMI — body 
mass index. PEFR — peak expiratory flow rates; FEF 25−75% — forced expiratory flow; FRC — functional residual capacity; RV — residual volume; TLC — total 
lung capacity; DLCO — single breath diffusing capacity; DLCO/VA — single breath diffusing capacity corrected for alveolar volume. NOA group — BMI < 25 kg/m2; 
OANMS group — BMI ≥ 25 kg/m2 without metabolic syndrome;  OAMS — BMI ≥ 25 kg/m2 with metabolic syndrome; avalues expressed as n (%) or mean ± SD; 
*p < 0.05 vs. NOA group; **p < 0.01 vs. NOA group; One-way ANOVA and Tukey’s post hoc test
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(50%) of mild persistent asthma patients. The 
results were statistically significant (p < 0.005); 
none of the groups had any patient diagnosed 
with severe persistent asthma. 
The levels of lipid profile and inflammatory 
markers in the NOA, OANMS and OAMS have 
been depicted in Table 4. The mean serum tri-
glyceride were highest in the OANMS group, the 
results being statistically significant (p < 0.005), 
however the mean HDL levels were the highest 
in the OANMS group, followed by the OAMS and 
the NOA groups, the difference was not statisti-
cally significant. Among inflammatory markers, 
mean FENO levels were the highest in the NOA 
group (p < 0.001) followed by the OANMS and 
the OAMS group. Subsequently, it was noted 
that IL-6 levels were highest in the OAMS group 
(p < 0.003), followed by the OANMS and the 
NOA group. The mean serum leptin levels were 
the highest in OANMS group (p < 001). 
Discussion
The primary objective of the study was to 
compare the NOA, OANMS and OAMS group 
patients with respect to asthma severity, quality of 
life, quality of sleep, OSA, inflammatory markers 
and sleep disordered breathing
The effect of obesity and metabolic syndrome 
on the severity of asthma at presentation is not 
well established. A retrospective cohort analysis 
of National Health and Nutrition Examination 
survey 2001−2002 and 2002−2004 reported 
2.63 fold-increased odds of moderate to severe 
asthma in centrally obese patients [19]. The 
current study had increased number of modera-
te persistent asthmatics in obese groups while 
non-obese asthmatics mainly suffered from mild 
intermittent and mild persistent asthma. Lazarus 
et al. have described in obesity a disproportionate 
reduction in FVC in comparison to FEV1 [20]. 
In the current study, no statistically significant 
reduction in FVC and FEV1 with increasing BMI 
was observed. However, mean percent predicted 
FRC in current study was the highest in NOA, 
decreasing in OANMS and further decreasing 
in OAMS groups (p < 0.005). These results are 
consistent with the literature [21]. Also the largest 
reduction in FEV1 and FVC in OAMS group might 
be attributed to additional effects of metabolic 
syndrome on obese asthmatics. 
Nakajima et al. concluded that impaired 
restrictive pulmonary function, but not obstruc-
tive pattern, might be associated with metabolic 
disorders and metabolic syndrome in a severity 
dependent manner [22]. This may give a possible 
explanation of significantly reduced lung volu-
me in OAMS group. The plausible explanation 
for this is increase in intra-abdominal pressure 
on the diaphragm and in fat mass on the chest 
wall leading to mass loading of the thorax, thus 
increasing the deflationary pressure and redu-
cing the compliance of lung and the respiratory 
system [23].
A prior study on 200 adult asthmatics by Ma-
alej et al. in Tunisia assessed quality of life by the 
Table 4. Lipid profile and Inflammatory markers in the study population (n = 60)a
Variable NOA (n = 20) OANMS (n = 20) OAMS (n = 20)
Lipid Profile
Serum Triglyceride (mg/dL)
HDL Cholesterol (mg/dL)
116.3 ± 93.3
35.7 ± 16.1
138.9 ± 51.1
39.1 ± 16.5
200.8 ± 95.7*, **
36.4 ± 14.1
Inflammatory markers
FENO (ppb)
S.Total IgE (IU/ml)
AEC (cells/cumm)
IL-5 (pg/ml)
IL-6 (pg/ml)
TNFa (units/ml)
Leptin (ng/dL)
Hs-CRP (mg/dL)
31.85 ± 11.82
1363.83 ± 1193.48
366.00 ± 262.11
36.85 ± 22.83
41.95 ± 32.21
194.55 ± 137.06
20.60 ± 14.37
14.14 ± 6.72
25.15 ± 15.42
1292.67 ± 1268.24
362.50 ± 216.34
18.79 ± 11.74
53.85 ± 40.88
208.15 ± 143.57
39.70 ± 16.93%
14.20 ± 6.83
15.85 ± 10.04^, ^^ 
1578.74 ± 1099.44
328.00 ± 266.56
33.60 ± 30.68
118.99 ± 88.06#, ##
267.00 ± 188.34
37.75 ± 19.54%%
14.23 ± 6.98
NOA — non-obese asthmatics; OANMS — obese asthmatics without metabolic syndrome; OAMS — obese asthmatics with metabolic syndrome, and BMI — body 
mass index; OSA — obstructive sleep apnea; HDL — high density lipoproteins; FENO — exhaled nitric oxide; AEC — absolute eosinophil count; IL-interleukin; TNF — 
tumor necrosis factor; hs-CRP — highly sensitive C-reactive protein; NOA group — BMI < 25 kg/m2; OANMS group — BMI ≥ 25 kg/m2 without metabolic syndrome; 
OAMS — BMI ≥ 25 kg/m2 with metabolic syndrome, avalues expressed as n (%) or mean ± SD; *p < 0.01 vs. NOA group **p < 0.01 vs. OANMS group; ^p < 0.01 
vs. NOA group; ^^p < 0.01 vs. OANMS group; #p < 0.01 vs. NOA group; ##p < 0.01 vs. OANMS group; %p < 0.01 vs. NOA group; %%p < 0.01 vs. OANMS group; 
One-way ANOVA and Tukey’s post hoc test
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AQVAT (Arabic version of the Asthma Quality of 
Life Questionnaire) [24]. The univariate analysis 
showed that obesity and overweight were asso-
ciated with a poorer quality of life (AQVAT > 6). 
Ermolova et al. reported in their assessment of the 
quality of life based on the short ShortForm-36 
questionnaire, a marked negative effect of asthma 
with metabolic syndrome patients in comparison 
to asthma without metabolic syndrome [25]. In 
the current study, similar poorer quality of life 
as assessed by the SGRQ score was the worst in 
OAMS group.
Sleep apnea is considered as a manifestation 
of metabolic syndrome, as there is a strong associa-
tion of OSA with obesity, systemic effect e.g. hy-
pertension and diabetes, overlapping with the fac-
tors associated with the metabolic syndrome [26]. 
The current study reported OAMS (55%) or 
OANMS (50%) groups were having higher risk 
of OSA as compared to NOA (20%), as assessed 
by ESS score. Similarly, using Berlin question-
naire a statistically significant difference could 
be found between NOA and OAMS groups. The 
potential mechanism for increased risk of OSA in 
asthmatics has been attributed to presence of per-
sistent airway mucosal inflammation in asthma, 
which may promote a  reduction in the surface 
area of the airways, including the upper airway. 
The reduction in surface area of pharynx provides 
a prime setting for the development of OSA [27]. 
The data regarding FENO levels in obese asth-
matics is conflicting; Ramasamy et al. found no 
difference in FENO levels related to obesity [23], 
whereas Komakula et al. observed the trend to-
wards increased FENO in obese adults with severe 
asthma [28]. The current study demonstrated 
significantly lower levels of FENO in OAMS in 
comparison to NOA and OANMS groups. These 
results are in line with a population-based study 
by Berg et al. in obese asthmatics that have shown 
negative correlation between BMI and FENO [26]. 
In our study the levels of IL-6 were significantly 
higher in OAMS group. The further increased 
levels found in metabolic syndrome are in line 
with a study by Kern et al. who have demonstrated 
the strongest relationship of IL-6 with obesity and 
insulin resistance [29]. The leptin levels in the 
present study were higher in obese asthmatics in 
comparison to non-obese, however presence of 
metabolic syndrome did not showed significant 
difference among obese asthmatics. The findings 
of present study are in agreement with the litera-
ture [30]. However, other inflammatory markers 
(IL-5, TNFa and hs-CRP) failed to demonstrate 
any statistical difference among the groups. Po-
sitive association of TNFa and hs-CRP levels with 
obesity has been documented in the literature [6]. 
The present study is limited by small number of 
patients enrolled. Hence, a large‐scale population 
based study in future may be planned for asses-
sing the effect of obesity and metabolic syndrome 
on asthma in Indian population. 
In conclusion, present study has shown that 
obese asthmatics especially those with comorbi-
dities like metabolic syndrome may be considered 
as a subtype of asthmatics having more severe 
asthma, poor quality of life, high risk of OSA, 
decreased lung volume (FRC), higher levels of 
inflammatory markers like leptin and IL-6 and 
high incidence of SDB. The obesity asthma group 
has been recently recognized as a new subphe-
notype in the GINA classification. Obesity may 
represent a contributory factor in poor control of 
asthma with standard asthma therapies. One of 
the unmet needs in asthma treatment is to develop 
personalized therapies targeted towards a specific 
phenotype. Large cohort studies with a longitu-
dinal follow up are required to better define the 
subgroups within the obesity asthma phenotype. 
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